← All trials
NCT01815632
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2014
- Primary completion
- Oct 31, 2019
- Completion date
- Oct 31, 2019
- First posted
- Mar 21, 2013
- Last posted
- Jun 27, 2018
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BristolLead sponsor
- University of BristolCollaborator
- Medical Research CouncilCollaborator
- NHS Blood and TransplantCollaborator
- University of BristolCollaborator
- University of NottinghamCollaborator
- Rosetrees TrustCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.